TY - JOUR
T1 - Immunotherapy for cancer treatment during pregnancy
AU - Borgers, Jessica S. W.
AU - Heimovaara, Joosje H.
AU - Cardonick, Elyce
AU - Dierickx, Daan
AU - Lambertini, Matteo
AU - Haanen, John B. A. G.
AU - Amant, Frédéric
N1 - Funding Information:
DD acted as a consultant for Sanofi, Roche, Atara, Incyte, Novartis, Amgen, and Takeda; received speaker honoraria from Sanofi, Incyte, Takeda, and Atara, outside the submitted work; and holds a mandate for Clinical and Translational Research from Kom op tegen Kanker. ML acted as a consultant for Roche, Novartis, Lilly, and AstraZeneca; and received speaker honoraria from Roche, Novartis, Lilly, Pfizer, Sandoz, and Takeda, outside the submitted work. JBAGH is adviser to Achilles Therapeutics, Bristol-Myers Squibb, BioNTech USA, Ipsen, Gadeta, Immunocore, Merck Sharpe & Dohme, Merck Serono, Molecular Partners, Neogene Therapeutics, Novartis, Pfizer, Roche–Genentech, Sanofi, Seattle Genetics, and Third Rock Ventures; is a stockholder in Neogene Therapeutics; and is a recipient of grants or research support from Bristol-Myers Squibb, Merck Sharpe & Dohme, Novartis, Neogene Therapeutics, Asher Bio, and BioNTech USA. All other authors declare no competing interests.
Publisher Copyright:
© 2021 Elsevier Ltd
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Immunotherapy has greatly improved outcomes for subgroups of patients with cancer. As indications keep expanding, there is an unmet need to gain a better understanding of the effect of these therapies on pregnancy and fertility. During pregnancy, substantial adaptations occur in the maternal immune system to maintain protection against pathogens while avoiding detrimental reactions to the semi-allogeneic fetus. The pathways involved in the establishment of this fetomaternal tolerance can be hijacked by cancers. Immunotherapies that target these inhibitory pathways, or that directly interact with the regulatory immune cells involved in tolerance mechanisms, might therefore result in complications during pregnancy. Similarly, by activating the patient's immune system with immunotherapy, a broad range of immune-related adverse events can occur that could negatively affect the fetus or impede a future desired pregnancy. This Review summarises preclinical and clinical data related to the use of immunotherapy during pregnancy, including all approved immune checkpoint inhibitors, recombinant cytokines, cell therapies, vaccines, and immunomodulatory drugs.
AB - Immunotherapy has greatly improved outcomes for subgroups of patients with cancer. As indications keep expanding, there is an unmet need to gain a better understanding of the effect of these therapies on pregnancy and fertility. During pregnancy, substantial adaptations occur in the maternal immune system to maintain protection against pathogens while avoiding detrimental reactions to the semi-allogeneic fetus. The pathways involved in the establishment of this fetomaternal tolerance can be hijacked by cancers. Immunotherapies that target these inhibitory pathways, or that directly interact with the regulatory immune cells involved in tolerance mechanisms, might therefore result in complications during pregnancy. Similarly, by activating the patient's immune system with immunotherapy, a broad range of immune-related adverse events can occur that could negatively affect the fetus or impede a future desired pregnancy. This Review summarises preclinical and clinical data related to the use of immunotherapy during pregnancy, including all approved immune checkpoint inhibitors, recombinant cytokines, cell therapies, vaccines, and immunomodulatory drugs.
UR - https://www.scopus.com/pages/publications/85120069858
U2 - 10.1016/S1470-2045(21)00525-8
DO - 10.1016/S1470-2045(21)00525-8
M3 - Review article
SN - 1470-2045
VL - 22
SP - e550-e561
JO - lancet oncology
JF - lancet oncology
IS - 12
ER -
SDG 3 Good Health and Well-being